Effect of <i>slc43a3</i> deletion on food and water consumption in male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Effect of <i>slc43a3</i> deletion on resting blood pressure (systolic and diastolic) and heart rate of male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Phase analysis data and within group correlations. by Aaron L. Sayler (19797446)

Subjects:

Effect of <i>slc43a3</i> deletion on the diurnal cycle of oxygen consumption (VO₂) in male and female mice. by Aaron L. Sayler (19797446)

Subjects:

Effect of <i>slc43a3</i> deletion on physical activity of male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Summary of measured parameters. by Aaron L. Sayler (19797446)

Subjects:

Effect of <i>slc43a3</i> deletion on metabolic performance parameters in male and female WT and KO mice. by Aaron L. Sayler (19797446)

Subjects:

Raw data. by Aaron L. Sayler (19797446)

Subjects:

Scatter plot for the significant Mendelian randomization (MR) association (P < 0.05) between mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Comparative Analysis of Chills Experience Across Three Groups: This table presents a detailed comparison of three groups (A, B, and C) in terms of their experiences with chills. It... by Felix Alexandre Schoeller (20988295)